The Baker Institute is committed to scientific excellence and our ‘2018 Best of Baker Awards’ recognise outstanding research achievement based on scientific publications. They demonstrate areas where scientific discoveries are likely to have significant impact in health and medical research.
Our focus now is on translating this research to develop new drugs and devices, to inform policy, to develop best-practice prevention and treatment guidelines, and to facilitate education programs for healthcare professionals.
This is how our research is making a difference to the health of Australians, and people around the world.
- A single-chain antibody-CD39 fusion protein targeting activated platelets protects from cardiac ischaemia/reperfusion injury (Basic Science)
- Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention (Clinical/Epidemiology)
- Defective cholesterol metabolism in haematopoietic stem cells promotes monocyte-driven atherosclerosis in rheumatoid arthritis (Basic Science)
- The productivity burden of diabetes at a population level (Clinical/Epidemiology)
- Evidence that TLR4 is not a receptor for saturated fatty acids but mediates lipid-induced inflammation by reprogramming macrophage metabolism
- Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque
- Airway microbiota dynamics uncover a critical window for interplay of pathogenic bacteria and allergy in childhood respiratory disease
- Characterising risk of in-hospital mortality following cardiac arrest using machine learning: a retrospective international registry study
- Diagnosis and significance of pulmonary microvascular disease in diabetes
- Diagnosis of nonischemic Stage B heart failure in type 2 diabetes mellitus: optimal parameters for prediction of heart failure
- Lipidomic profiles of the heart and circulation in response to exercise versus cardiac pathology: a resource of potential biomarkers and drug targets
- High baseline levels of tumor necrosis factor receptor 1 are associated with progression of kidney disease in indigenous australians with diabetes: the eGFR follow-up study